Healthcare provider profile · identity verified

Anne E Moyer, P.A.

Physician Assistant · OCALA, FL · NPI 1609929819

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	422	158
Amlodipine Besylate	Amlodipine Besylate	275	107
Rosuvastatin Calcium	Rosuvastatin Calcium	261	99
Lisinopril	Lisinopril	215	81
Losartan Potassium	Losartan Potassium	209	81
Metformin Hcl	Metformin Hcl	196	75
Levothyroxine Sodium	Levothyroxine Sodium	182	61
Omeprazole	Omeprazole	178	79
Gabapentin	Gabapentin	177	81
Prednisone	Prednisone	153	102
Pantoprazole Sodium	Pantoprazole Sodium	146	63
Albuterol Sulfate Hfa	Albuterol Sulfate	141	66
Tizanidine Hcl	Tizanidine Hcl	138	71
Famotidine	Famotidine	124	65
Trazodone Hcl	Trazodone Hcl	107	49
Meloxicam	Meloxicam	102	47
Montelukast Sodium	Montelukast Sodium	97	45
Jardiance	Empagliflozin	91	31
Furosemide	Furosemide	89	36
Metoprolol Tartrate	Metoprolol Tartrate	88	33
Metoprolol Succinate	Metoprolol Succinate	86	33
Glimepiride	Glimepiride	85	30
Hydrochlorothiazide	Hydrochlorothiazide	82	35
Azithromycin	Azithromycin	79	70
Carvedilol	Carvedilol	72	27
Tamsulosin Hcl	Tamsulosin Hcl	64	25
Ezetimibe	Ezetimibe	61	33
Eliquis	Apixaban	59	19
Bupropion Xl	Bupropion Hcl	58	25
Glipizide	Glipizide	57	18
Allopurinol	Allopurinol	56	21
Amoxicillin	Amoxicillin	52	45
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	18
Potassium Chloride	Potassium Chloride	47	19
Simvastatin	Simvastatin	47	19
Clopidogrel	Clopidogrel Bisulfate	46	19
Duloxetine Hcl	Duloxetine Hcl	46	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	13
Trulicity	Dulaglutide	46	11
Topiramate	Topiramate	45	17
Pravastatin Sodium	Pravastatin Sodium	43	15
Lorazepam	Lorazepam	40	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	39	13
Alprazolam	Alprazolam	38	11
Sertraline Hcl	Sertraline Hcl	38	14
Venlafaxine Hcl Er	Venlafaxine Hcl	38	18
Escitalopram Oxalate	Escitalopram Oxalate	37	11
Mirtazapine	Mirtazapine	36	15
Valsartan	Valsartan	36	12
Nitroglycerin	Nitroglycerin	35	16
Zolpidem Tartrate	Zolpidem Tartrate	35	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	12
Buspirone Hcl	Buspirone Hcl	31	17
Ozempic	Semaglutide	31	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	31	12
Ropinirole Hcl	Ropinirole Hcl	30	12
Doxycycline Hyclate	Doxycycline Hyclate	29	26
Pentoxifylline	Pentoxifylline	29	14
Citalopram Hbr	Citalopram Hydrobromide	28	11
Hydralazine Hcl	Hydralazine Hcl	28	12
Lansoprazole	Lansoprazole	28	suppressed
Mounjaro	Tirzepatide	28	suppressed
Nifedipine Er	Nifedipine	28	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	28	11
Alendronate Sodium	Alendronate Sodium	27	12
Metformin Hcl Er	Metformin Hcl	27	11
Spironolactone	Spironolactone	27	12
Fluticasone Propionate	Fluticasone Propionate	26	14
Fenofibrate	Fenofibrate	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Meclizine Hcl	Meclizine Hcl	25	20
Pregabalin	Pregabalin	25	suppressed
Farxiga	Dapagliflozin Propanediol	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	15
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	11
Januvia	Sitagliptin Phosphate	21	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	12
Baclofen	Baclofen	19	11
Clonidine Hcl	Clonidine Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Glipizide Er	Glipizide	18	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Finasteride	Finasteride	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Temazepam	Temazepam	17	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	16	suppressed
Risperidone	Risperidone	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Lactulose	Lactulose	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Atrovent Hfa	Ipratropium Bromide	13	suppressed
Carisoprodol	Carisoprodol	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Repatha Syringe	Evolocumab	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Atenolol	Atenolol	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Linzess	Linaclotide	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Benzonatate	Benzonatate	11	11
Cefdinir	Cefdinir	11	11
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error